Roobol MJ - Search Results

1

Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.

Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Bul M, et al. Among authors: roobol mj. Eur Urol. 2011 Apr;59(4):498-505. doi: 10.1016/j.eururo.2011.01.001. Epub 2011 Feb 18. Eur Urol. 2011. PMID: 21334136 Free article. Clinical Trial.

2

Analytical issues on prostate-specific antigen in relation to prostate cancer screening.

Blijenberg BG, Roobol M, Schröder FH. Blijenberg BG, et al. Clin Biochem. 1998 Nov;31(8):633-9. doi: 10.1016/s0009-9120(98)00072-1. Clin Biochem. 1998. PMID: 9876895 Clinical Trial.

3

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

4

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

5

The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.

Vis AN, Hoedemaeker RF, Roobol M, Schröder FH, van der Kwast TH. Vis AN, et al. Cancer. 2001 Aug 1;92(3):524-34. doi: 10.1002/1097-0142(20010801)92:3<524::aid-cncr1351>3.0.co;2-a. Cancer. 2001. PMID: 11505396

6

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

Roobol MJ, Kranse R, van der Cruijsen IW, Schröder FH. Roobol MJ, et al. Urology. 2002 Jan;59(1):91-6. doi: 10.1016/s0090-4295(01)01479-0. Urology. 2002. PMID: 11796288 Clinical Trial.

7

Serendipity in detecting disease in low prostate-specific antigen ranges.

Vis AN, Kranse R, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. BJU Int. 2002 Mar;89(4):384-9. doi: 10.1046/j.1464-4096.2001.01868.x. BJU Int. 2002. PMID: 11872029 Clinical Trial.

8

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Raaijmakers R, et al. Among authors: roobol mj. Urology. 2002 Nov;60(5):826-30. doi: 10.1016/s0090-4295(02)01958-1. Urology. 2002. PMID: 12429309

9

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

Roobol MJ, Kranse R, de Koning HJ, Schröder FH. Roobol MJ, et al. Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083. Urology. 2004. PMID: 14972478

10

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH. Raaijmakers R, et al. Among authors: roobol mj. Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028. Urology. 2004. PMID: 14972481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

501 results

Search Page

Filters